Slide 1: VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children
Abstract ID: 001928 VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children Aged 4-7 Years With Atopic Comorbidities Juan Trujillo,1 Jonathan Hourihane,2,3 Nicolette Arends,4 Katharina Blumchen,5 Paul J. Turner,6 Katharine Bee,7 Anne-Sophie Chhim,7 Esther
Slide 2: Author Disclosures
Author Disclosures Presen&ng author disclosures: • JT has received honoraria from ALK-Abelló, Menarini Group, and Thermo Fisher Scien>fic; payment for expert tes>mony from Aimmune Therapeu>cs and ALK-Abelló; and support for aDending mee>ngs from Menarini Group Co-author disclosures: • JH has received
Slide 3: Epicutaneous Immunotherapy for Peanut Allergy
Epicutaneous Immunotherapy for Peanut Allergy In the Phase 3 VITESSE trial, a greater proporBon of children with peanut allergy VIASKIN® Peanut Patch aged 4 through 7 years achieved desensiBzaBon at 12 months with epicutaneous immunotherapy via the VIASKIN® Peanut Patch (250 µg of peanut protein) vs
Slide 4: VITESSE Study Design: 12-Month, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
VITESSE Study Design: 12-Month, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial1 DBPC period Open-label extension • Children with peanut allergy (aged 4 through 7 years)1 VIASKIN® VIASKIN® • 87 sites in Australia, Canada, Europe, Peanut Peanut SU assessment* and the USA1 Patch Patch • Ke
Slide 5: Participant Demographics and Baseline Characteristics Were Well Balanced Between Study Groups
Participant Demographics and Baseline Characteristics Were Well Balanced Between Study Groups VIASKIN® Peanut Patch Placebo ITT popula&on (n=438) (n=216) Age, years, median (Q1, Q3) 5.7 (4.8, 6.9) 5.7 (4.8, 6.7) Sex, n (%) Male 265 (60.5) 142 (65.7) Female 172 (39.3) 74 (34.3) Undifferentiated 1 (0.
Slide 6: Met the Primary Endpoint and Demonstrated Significantly Greater Responder Rates vs Placebo
VIASKIN® Peanut Patch Met the Primary Endpoint and Demonstrated Significantly Greater Responder Rates vs Placebo Treatment Responders* at Month 12 (ITT PopulaCon) 50 p<0.0001† 46.6 40 ParGcipants (%) Δ=31.8% 30 (95% CI: 24.5, 39.0) 20 10 14.8 0 VIASKIN® Peanut Patch Placebo (n=438) (n=216) *Responder
Slide 7: Treatment Responder Rates Were Significantly Greater With VIASKIN vs Placebo Regardless of Comorbidity Status
Treatment Responder Rates Were Significantly Greater With VIASKIN® Peanut Patch vs Placebo Regardless of Comorbidity Status Concomitant Asthma Concomitant Atopic DermaCCs Concomitant Food Allergies at Baseline at Baseline at Baseline 60% p<0.0001 60% p<0.0001 60% p<0.0001 p<0.0001 p<0.0001 p<0.0001 5
Slide 8: Overview of TEAEs for Participants With and Without Comorbidities at Baseline
Overview of TEAEs for ParQcipants With and Without ComorbidiQes at Baseline With asthma Without asthma With AD Without AD With CFA Without CFA VIASKIN® VIASKIN® VIASKIN® VIASKIN® VIASKIN® VIASKIN® Peanut Peanut Peanut Peanut Peanut Peanut Patch Placebo Patch Placebo Patch Placebo Patch Placebo Patch
Slide 9: Overview of Treatment-Related TEAEs for Participants With and Without Comorbidities at Baseline
Overview of Treatment-Related TEAEs for Participants With and Without Comorbidities at Baseline With asthma Without asthma With AD Without AD With CFA Without CFA VIASKIN® VIASKIN® VIASKIN® VIASKIN® VIASKIN® VIASKIN® Peanut Peanut Peanut Peanut Peanut Peanut Patch Placebo Patch Placebo Patch Placebo
Slide 10: Summary
Summary EPIT via the VIASKIN® Peanut Patch (250 µg) resulted in statistically significant VIASKIN® Peanut Patch efficacy vs placebo (p<0.0001) in children with peanut allergy with ongoing asthma, atopic dermatitis, or concomitant food allergy • These results were consistent with those observed in th
Slide 11: Thank you
Abstract ID: 001928 Thank you Presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting June 12-15, 2026 | Istanbul, Türkiye